Promising Long-Term Survival Seen With Frontline Blinatumomab for B-ALL
Researchers sought to determine whether adding blinatumomab to standard frontline treatment of hyper-CVAD would improve survival in patients with B-ALL.
Acute Lymphoblastic Leukemia
FDA Approves Additional Dosing Schedule for Rylaze
The MWF dosing option was approved under the Real-Time Oncology Review program based on data from the intramuscular administration part of a phase 2/3 trial.
Novel Tri-Specific Antibody May Effectively Eliminate B-ALL Cells
Researchers sought to determine whether a CD19/CD22/CD3-targeting tri-specific antibody would prevent immune escape in patients with B-ALL.
FLT3-Targeted CAR-T Cells Show Antitumor Activity in KMT2A-Rearranged B-Cell Acute Lymphoblastic Leukemia
Researchers sought to determine whether FLT3-targeted CAR-T cells could have antitumor activity in patients with B-ALL with KMT2A rearrangement.
T-Cell Immunity May Impact Outcomes in Patients With Acute Lymphoblastic Leukemia
Researchers sought to determine whether T-cell immunity impacts treatment outcomes in ALL.
Unrelated Cord Blood May Be Effective Alternative to HLA-Matched Sibling Donor in Adult B-ALL
Researchers sought to determine whether use of UBC for allo-HSCT would have comparable efficacy with a HLA-matched sibling donor in patients with B-ALL.
Costs of ALL Treatment Higher for Patients Diagnosed After 10 Years of Age
The cost of care was 50% to 70% higher among patients aged 10-30 years at diagnosis, compared with patients who were younger than 10 years of age, researchers found.
Nonresponse to Tisagenlecleucel Associated With Poor OS in B-Cell Acute Lymphoblastic Leukemia
Researchers sought to determine whether a lack of response to tisagenlecleucel had a link with survival in patients with B-ALL.
Exploring JAK/STAT Inhibition in the Prevention and Treatment of B-ALL
Researchers sought to determine whether the JAK/STAT pathway would be actionable for the treatment of patients with B-ALL.
Chemotherapy-Free Regimen Shows Promise in Ph+ Acute Lymphoblastic Leukemia
Researchers sought to determine whether ponatinib plus blinatumomab would be effective for patients with Ph+ ALL.
- Loading...
Loading...
Next post in SOHO 2022
Loading... 
Loading...